Female rats were neonatally androgenized (NA) by administering 1.25 mg of testosterone propionate at 3 days of age. At 21–23 days of age, groups of 12 animals each were blinded (BLD), olfactory bulbectomized (ANOS) and pineal-ectomized (PX) either alone or in combination. At 11 weeks of age all animals were ovariectomized, implanted with atrial catheters and given 0.5 mg polyestradiol phosphate. At 12 weeks of age, animals were attached to catheter extensions and blood samples obtained at 09.00, 11.00, 13.00, 15.00, 17.00, 19.00 and 21.00 h. The plasma prolactin (PRL) pattern of NA control animals consisted of elevated basal values at 11.00 and 13.00 h with an afternoon peak at 17.00 h. Anosmic and PX animals had a PRL pattern similar to that of the control. Animals BLD or BLD + ANOS had significantly lower plasma PRL values than sham-operated animals. Animals BLD + PX had PRL values comparable to PX alone. The diurnal PRL pattern observed for NA control animals was still evident in all experimental animals. Blinding + ANOS resulted in a significant decrease in ovarian and oviductal weights and attenuated the estrogen-induced increase in uterine weight. The evidence indicated that the elevated morning PRL levels observed in NA rats was not due to an altered function of the pineal gland and that BLD + ANOS blunted the action of exogenous estrogen on uterine weight.

Keywords:
Neonatally androgenized, Plasma prolactin levels, Blinding, Olfactory bulbectomy, Pinealectomy, Prolactin biorhythm, Anosmia, Sensory deprivation
This content is only available via PDF.
© 1983 S. Karger AG, Basel
1983
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.